EDP Sciences logo
Subscriber Authentication Point
Search
Menu
Home All issues Volume 21 / No 1 (Janvier 2005) Med Sci (Paris), 21 1 (2005) 37-42 References
Free Access
Issue
Med Sci (Paris)
Volume 21, Number 1, Janvier 2005
Page(s) 37 - 42
Section M/S Revues
DOI https://doi.org/10.1051/medsci/200521137
Published online 15 January 2005
  1. Cech TR. Beginning to understand the end of the chromosome. Cell 2004; 116 : 273–9. [Google Scholar]
  2. Masutomi K, Yu EY, Khurts S, et al. Telomerase maintains telomere structure in normal human cells. Cell 2003; 114 : 241–53. [Google Scholar]
  3. Gisselsson D. Chromosome instability in cancer : how, when, and why ? Adv Cancer Res 2003; 87 : 1–29. [Google Scholar]
  4. O’Sullivan JN, Bronner MP, Brentnall TA, et al. Chromosomal instability in ulcerative colitis is related to telomere shortening. Nat Genet 2002; 32 : 280–4. [Google Scholar]
  5. Artandi SE, Chang S, Lee SL, et al. Telomere dysfunction promotes non-reciprocal translocations and epithelial cancers in mice. Nature 2000; 406 : 641–5. [Google Scholar]
  6. Rudolph KL, Millard M, Bosenberg MW, DePinho RA. Telomere dysfunction and evolution of intestinal carcinoma in mice and humans. Nat Genet 2001; 28 : 155–9. [Google Scholar]
  7. Gabet AS, Mortreux F, Charneau P, et al. Inactivation of hTERT transcription by Tax. Oncogene 2003; 22 : 3734–41. [Google Scholar]
  8. Kim NW, Piatyszek MA, Prowse KR, et al. Specific associations of human telomerase activity with immortal cells and cancer. Science 1994; 266 : 2011–4. [Google Scholar]
  9. Greenberg RA, Chin L, Femino A, et al. Short dysfunctional telomeres impair tumorigenesis in the INK4a(delta2/3) cancer-prone mouse. Cell 1999; 97 : 515–25. [Google Scholar]
  10. Gonzalez-Suarez E, Samper E, Flores JM, Blasco MA. Telomerase-deficient mice with short telomeres are resistant to skin tumorigenesis. Nat Genet 2000; 26 : 114–7. [Google Scholar]
  11. Farazi PA, Glickman J, Jiang S, et al. Differential impact of telomere dysfunction on initiation and progression of hepatocellular carcinoma. Cancer Res 2003; 63 : 5021–7. [Google Scholar]
  12. Hahn WC, Counter CM, Lundberg AS, et al. Creation of human tumour cells with defined genetic elements. Nature 1999; 400 : 464–8. [Google Scholar]
  13. Elenbaas B, Spirio L, Koerner F, et al. Human breast cancer cells generated by oncogenic transformation of primary mammary epithelial cells. Genes Dev 2001; 15 : 50–65. [Google Scholar]
  14. Lundberg AS, Randell SH, Stewart SA, et al. Immortalization and transformation of primary human airway epithelial cells by gene transfer. Oncogene 2002; 21 : 4577–86. [Google Scholar]
  15. Bryan TM, Englezou A, Dalla-Pozza L, et al. Evidence for an alternative mechanism for maintaining telomere length in human tumors and tumor-derived cell lines. Nat Med 1997; 3 : 1271–4. [Google Scholar]
  16. Seger YR, Garcia-Cao M, Piccinin S, et al. Transformation of normal human cells in the absence of telomerase activation. Cancer Cell 2002; 2 : 401–13. [Google Scholar]
  17. Lazarov M, Kubo Y, Cai T, et al. CDK4 coexpression with Ras generates malignant human epidermal tumorigenesis. Nat Med 2002; 8 : 1105–14. [Google Scholar]
  18. Brun C, Marcand S, Gilson E. Proteins that bind to double-stranded regions of telomeric DNA. Trends Cell Biol 1997; 7 : 317–24. [Google Scholar]
  19. de Lange T. Protection of mammalian telomeres. Oncogene 2002; 21 : 532–40. [Google Scholar]
  20. Ancelin K, Brunori M, Bauwens S, et al. Targeting assay to study the cis functions of human telomeric proteins : evidence for inhibition of telomerase by TRF1 and for activation of telomere degradation by TRF2. Mol Cell Biol 2002; 22 : 3474–87. [Google Scholar]
  21. Miyachi K, Fujita M, Tanaka N, et al. Correlation between telomerase activity and telomeric-repeat binding factors in gastric cancer. J Exp Clin Cancer Res 2002; 21 : 269–75. [Google Scholar]
  22. Kondo T, Oue N, Yoshida K, et al. Expression of POT1 is associated with tumor stage and telomere length in gastric carcinoma. Cancer Res 2004; 64 : 523–9. [Google Scholar]
  23. Aragona M, De Divitiis O, La Torre D, et al. Immunohistochemical TRF1 expression in human primary intracranial tumors. Anticancer Res 2001; 21 : 2135–9. [Google Scholar]
  24. Saito K, Yagihashi A, Nasu S, et al. Gene expression for suppressors of telomerase activity (telomeric-repeat binding factors) in breast cancer. Jpn J Cancer Res 2002; 93 : 253–8. [Google Scholar]
  25. Ohyashiki JH, Hayashi S, Yahata N, et al. Impaired telomere regulation mechanism by TRF1 (telomere-binding protein), but not TRF2 expression, in acute leukemia cells. Int J Oncol 2001; 18 : 593–8. [Google Scholar]
  26. Nakanishi K, Kawai T, Kumaki F, et al. Expression of mRNAs for telomeric repeat binding factor (TRF)-1 and TRF2 in atypical adenomatous hyperplasia and adenocarcinoma of the lung. Clin Cancer Res 2003; 9 : 1105–11. [Google Scholar]
  27. Stewart SA, Hahn WC, O’Connor BF, et al. Telomerase contributes to tumorigenesis by a telomere length-independent mechanism. Proc Natl Acad Sci USA 2002; 99 : 12606–11. [Google Scholar]
  28. Smith LL, Coller HA, Roberts JM. Telomerase modulates expression of growth-controlling genes and enhances cell proliferation. Nat Cell Biol 2003; 5 : 474–9. [Google Scholar]
  29. Griffith JD, Comeau L, Rosenfield S, et al. Mammalian telomeres end in a large duplex loop. Cell 1999; 97 : 503–14. [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.